SYGNIS AG

EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Announces Proposed Combination of Business with GENETRIX' subsidiary X-Pol

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Contracts

18.07.2012

Ad hoc-Release according to § 15 WpHG
SYGNIS Announces Proposed Combination of Business with GENETRIX' subsidiary
X-Pol

Heidelberg, July18,2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74;
Prime Standard) and GENETRIX Life Sciences, A.B., announced today, that the
biotechnology companies have signed a Term Sheet under which the companies
propose to combine GENETRIX Life Sciences, A.B.'s DNA sequencing subsidiary
X-Pol Biotech, S.L., (Madrid, Spain) and SYGNIS Pharma AG. Goal is to develop
and market X-Pol Biotech, S.L.'s DNA sequencing technologies and products.
SYGNIS Pharma AG will acquire 100% ownership of X-Pol Biotech, S.L., by way of
capital increase against contribution in kind and therefore X-Pol Biotech, S.L.,
will become a 100% subsidiary of SYGNIS Pharma AG. According to the business
valuation as of today and subject to a corresponding resolution of the
shareholders of SYGNIS Pharma AG, the existing shareholders of X-Pol Biotech,
S.L., will hold 77.5% of all shares in SYGNIS Pharma AG after the proposed
transaction. The executive and supervisory boards of both companies have voted
unanimously for the proposed key terms of the transaction. The transaction is
subject to an exemption granted by BaFin from the obligations pursuant to
Section 35 of the German Takeover Act (Wertpapiererwerbs- und Übernahmegesetz),
in particular to submit a mandatory tender offer to the existing shareholders of
SYGNIS Pharma AG in connection with the capital increase of SYGNIS Pharma AG. It
is also dependent on the approval of SYGNIS Pharma AG's shareholders at the next
shareholders' meeting. 
**** end of ad hoc ****
For further information please contact:

SYGNIS Pharma AG



Peter Willinger 
Tel: +49 6221 454 836
Email: {peter.willinger@sygnis.de}





### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from
the established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.
###


Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: